Tivic Health Systems Inc

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

VBIO$0.54+6.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

(in thousands)

	Years Ended December 31,
	2023	2022
Cash flows from operating activities
Net loss	$(8,244)	$(10,096)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	271	398
Depreciation	8	10
Amortization of right-of-use asset	174	164
Reserve for inventory obsolescence	32	—
Changes in operating assets and liabilities:
Accounts receivable	(67)	1
Inventory	75	(434)
Prepaid expenses and other current assets	(92)	558
Accounts payable	(610)	534
Accrued expenses	103	109
Lease liabilities	(161)	(178)
Other assets	—	15
Net cash used in operating activities	(8,511)	(8,919)
Cash flows from investing activities
Acquisition of property and equipment	(118)	(11)
Net cash used in investing activities	(118)	(11)
Cash flows from financing activities
Proceeds from exercise of stock options	—	56
Proceeds from issuance of common stock, net of issuance costs	8,507	—
Offering costs in advance of sale of common stock	—	(584)
Net cash provided by (used in) financing activities	8,507	(528)
Net decrease in cash and cash equivalents	(122)	(9,458)
Cash and cash equivalents
Beginning of period	3,517	12,975
End of period	$3,395	$3,517
Supplemental disclosure on noncash financing activities
Issuance of common stock warrant	$363	$—
Deferred offering costs charged to additional paid-in-capital	$584	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.